Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
Current oral anti-coagulation for atrial fibrillation is most commonly performed with
warfarin. Warfarin is a vitamin K antagonist that has been shown in non-randomized trials to
increase vascular calcification. Increased vascular calcification has been tied to increased
cardiovascular events (CVE). This study will randomize patients currently taking warfarin to
either continue on warfarin or be switched to rivaroxaban. Rivaroxaban is an oral
anti-coagulant that works by inhibiting Factor Xa, and has no interaction with vitamin K.
This study is a randomized, open label study that will randomize 120 patients and have them
undergo blood tests and a calcium scan at baseline, and again after 12 months. Patients will
be seen quarterly for examinations, safety checks and supply of rivaroxaban, as well as
follow up INR testing for warfarin.
Phase:
Phase 4
Details
Lead Sponsor:
Los Angeles Biomedical Research Institute Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center